Kezar Life Sciences to Present at Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on November 14, 2018, at 8:00 am GMT.
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in a Phase 1b trial, with a Phase 2 trial in lupus nephritis patients expected to initiate during the first half of 2019. Kezar is also poised to expand its development programs throughout 2019 with plans to initiate multiple Phase 2 trials of KZR-616 in up to four additional autoimmune indications, and to nominate its first protein secretion candidate to treat cancer. For more information, visit www.kezarlifesciences.com.
CONTACTS:Alex Gray, Burns McClellan, Inc., on behalf of Kezar Life Sciences212-213-0006 firstname.lastname@example.org